MTNR1B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan

Table 6 Cumulative effect of MTNR1B single-nucleotide polymorphism associated with 5-year overall survival of colorectal cancer patients

	No. of subjects	No. of cases (%)	Crude		Adjusteda
			HR	95%CI	HR	95%CI
No. of SNP risk genotypes
0	41	3 (7.3)	1.00	Referent	1.00	Referent
1	25	4 (16.0)	2.27	(0.51 to 10.1)	2.60	(0.55 to 12.2)
2	7	3 (42.9)	6.40	(1.29 to 317)	6.89	(1.16 to 41.0)
3	1	0 (0)	N/A	N/A	N/A	N/A
4	18	7 (38.9)	7.60	(1.96 to 29.5)	14.0	(2.94 to 66.3)
P for trend				< 0.001		< 0.001
≥ 2 of SNP risk genotypes	26	10 (38.5)	4.00	(1.58 to 10.1)	5.81	(2.03 to 16.6)

^aAdjusted for age, sex, stage, adjuvant chemotherapy, tumor location and the methylation status of CDKN2A, MLH1 and MGMT gene. SNP: Single-nucleotide polymorphism; U: Unmethylation; M: Methylation; HR: Hazard ratio; N/A: Not applicable.